BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mitra S, Duggineni S, Koolpe M, Zhu X, Huang Z, Pasquale EB. Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry. 2010;49:6687-6695. [PMID: 20677833 DOI: 10.1021/bi1006223] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Qu B, Han Y, Liang T, Zhang C, Hou G, Gao F. Evaluation of a novel EphA2 targeting peptide for triple negative breast cancer based on radionuclide molecular imaging. Arabian Journal of Chemistry 2022. [DOI: 10.1016/j.arabjc.2022.104211] [Reference Citation Analysis]
2 Udompholkul P, Baggio C, Gambini L, Sun Y, Zhao M, Hoffman RM, Pellecchia M. Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates. Molecules 2021;26:3687. [PMID: 34204178 DOI: 10.3390/molecules26123687] [Reference Citation Analysis]
3 Salem AF, Gambini L, Billet S, Sun Y, Oshiro H, Zhao M, Hoffman RM, Bhowmick NA, Pellecchia M. Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model. Cancers (Basel) 2020;12:E2854. [PMID: 33023262 DOI: 10.3390/cancers12102854] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 London M, Gallo E. The EphA2 and cancer connection: potential for immune-based interventions. Mol Biol Rep 2020;47:8037-48. [PMID: 32990903 DOI: 10.1007/s11033-020-05767-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Salem AF, Gambini L, Udompholkul P, Baggio C, Pellecchia M. Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents. Pharmaceuticals (Basel) 2020;13:E90. [PMID: 32397624 DOI: 10.3390/ph13050090] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
6 Giorgio C, Zanotti I, Lodola A, Tognolini M. Ephrin or not? Six tough questions on Eph targeting. Expert Opin Ther Targets 2020;24:403-15. [PMID: 32197575 DOI: 10.1080/14728222.2020.1745187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Incerti M, Russo S, Corrado M, Giorgio C, Ballabeni V, Chiodelli P, Rusnati M, Scalvini L, Callegari D, Castelli R, Vacondio F, Ferlenghi F, Tognolini M, Lodola A. Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties. Eur J Med Chem 2020;189:112083. [PMID: 32000051 DOI: 10.1016/j.ejmech.2020.112083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lingasamy P, Tobi A, Haugas M, Hunt H, Paiste P, Asser T, Rätsep T, Kotamraju VR, Bjerkvig R, Teesalu T. Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery. Biomaterials 2019;219:119373. [PMID: 31374479 DOI: 10.1016/j.biomaterials.2019.119373] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
9 Gomez-Soler M, Petersen Gehring M, Lechtenberg BC, Zapata-Mercado E, Hristova K, Pasquale EB. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling. J Biol Chem 2019;294:8791-805. [PMID: 31015204 DOI: 10.1074/jbc.RA119.008213] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
10 Patil MA, Upadhyay AK, Hernandez-Lagunas L, Good R, Carpenter TC, Sucharov CC, Nozik-Grayck E, Kompella UB. Targeted delivery of YSA-functionalized and non-functionalized polymeric nanoparticles to injured pulmonary vasculature. Artif Cells Nanomed Biotechnol 2018;46:S1059-66. [PMID: 30450979 DOI: 10.1080/21691401.2018.1528984] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Möser C, Lorenz JS, Sajfutdinow M, Smith DM. Pinpointed Stimulation of EphA2 Receptors via DNA-Templated Oligovalence. Int J Mol Sci 2018;19:E3482. [PMID: 30404153 DOI: 10.3390/ijms19113482] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
12 Gambini L, Salem AF, Udompholkul P, Tan XF, Baggio C, Shah N, Aronson A, Song J, Pellecchia M. Structure-Based Design of Novel EphA2 Agonistic Agents with Nanomolar Affinity in Vitro and in Cell. ACS Chem Biol 2018;13:2633-44. [PMID: 30110533 DOI: 10.1021/acschembio.8b00556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
13 Mercurio FA, Pirone L, Di Natale C, Marasco D, Pedone EM, Leone M. Sam domain-based stapled peptides: Structural analysis and interaction studies with the Sam domains from the EphA2 receptor and the lipid phosphatase Ship2. Bioorg Chem 2018;80:602-10. [PMID: 30036816 DOI: 10.1016/j.bioorg.2018.07.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
14 Salem AF, Wang S, Billet S, Chen JF, Udompholkul P, Gambini L, Baggio C, Tseng HR, Posadas EM, Bhowmick NA, Pellecchia M. Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide-Drug Conjugate. J Med Chem 2018;61:2052-61. [PMID: 29470068 DOI: 10.1021/acs.jmedchem.7b01837] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
15 Singh DR, Kanvinde P, King C, Pasquale EB, Hristova K. The EphA2 receptor is activated through induction of distinct, ligand-dependent oligomeric structures. Commun Biol 2018;1:15. [PMID: 30271902 DOI: 10.1038/s42003-018-0017-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
16 Zhao J, Zhao F, Wang X, Fan X, Wu G. Secondary nuclear targeting of mesoporous silica nano-particles for cancer-specific drug delivery based on charge inversion. Oncotarget 2016;7:70100-12. [PMID: 27661121 DOI: 10.18632/oncotarget.12149] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
17 Kim MA, Yoon HS, Park SH, Kim DY, Pyo A, Kim HS, Min JJ, Hong Y. Engineering of monobody conjugates for human EphA2-specific optical imaging. PLoS One 2017;12:e0180786. [PMID: 28686661 DOI: 10.1371/journal.pone.0180786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Riedl SJ, Pasquale EB. Targeting the Eph System with Peptides and Peptide Conjugates. Curr Drug Targets 2015;16:1031-47. [PMID: 26212263 DOI: 10.2174/1389450116666150727115934] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
19 Barquilla A, Lamberto I, Noberini R, Heynen-Genel S, Brill LM, Pasquale EB. Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation. Mol Biol Cell 2016;27:2757-70. [PMID: 27385333 DOI: 10.1091/mbc.E16-01-0048] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
20 Singh DR, Pasquale EB, Hristova K. A small peptide promotes EphA2 kinase-dependent signaling by stabilizing EphA2 dimers. Biochim Biophys Acta 2016;1860:1922-8. [PMID: 27281300 DOI: 10.1016/j.bbagen.2016.06.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
21 Bhunia D, Saha A, Adak A, Das G, Ghosh S. A dual functional liposome specifically targets melanoma cells through integrin and ephrin receptors. RSC Adv 2016;6:113487-91. [DOI: 10.1039/c6ra23864e] [Cited by in Crossref: 7] [Article Influence: 1.2] [Reference Citation Analysis]
22 Echalier C, Kalistratova A, Ciccione J, Lebrun A, Legrand B, Naydenova E, Gagne D, Fehrentz J, Marie J, Amblard M, Mehdi A, Martinez J, Subra G. Selective homodimerization of unprotected peptides using hybrid hydroxydimethylsilane derivatives. RSC Adv 2016;6:32905-14. [DOI: 10.1039/c6ra06075g] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
23 Giorgio C, Russo S, Incerti M, Bugatti A, Vacondio F, Barocelli E, Mor M, Pala D, Hassan-Mohamed I, Gioiello A, Rusnati M, Lodola A, Tognolini M. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. Biochem Pharmacol 2016;99:18-30. [PMID: 26462575 DOI: 10.1016/j.bcp.2015.10.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Callegari D, Pala D, Scalvini L, Tognolini M, Incerti M, Rivara S, Mor M, Lodola A. Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists. Molecules 2015;20:17132-51. [PMID: 26393553 DOI: 10.3390/molecules200917132] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
25 Park SH, Park S, Kim DY, Pyo A, Kimura RH, Sathirachinda A, Choy HE, Min JJ, Gambhir SS, Hong Y. Isolation and Characterization of a Monobody with a Fibronectin Domain III Scaffold That Specifically Binds EphA2. PLoS One 2015;10:e0132976. [PMID: 26177208 DOI: 10.1371/journal.pone.0132976] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
26 Wu B, Wang S, De SK, Barile E, Quinn BA, Zharkikh I, Purves A, Stebbins JL, Oshima RG, Fisher PB, Pellecchia M. Design and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. Chem Biol 2015;22:876-87. [PMID: 26165155 DOI: 10.1016/j.chembiol.2015.06.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
27 Herington AC, Mertens-Walker I, Lisle JE, Maharaj M, Stephenson SA. Inhibiting Eph kinase activity may not be "Eph"ective for cancer treatment. Growth Factors 2014;32:207-13. [PMID: 25413947 DOI: 10.3109/08977194.2014.985293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Barquilla A, Pasquale EB. Eph receptors and ephrins: therapeutic opportunities. Annu Rev Pharmacol Toxicol 2015;55:465-87. [PMID: 25292427 DOI: 10.1146/annurev-pharmtox-011112-140226] [Cited by in Crossref: 166] [Cited by in F6Publishing: 164] [Article Influence: 20.8] [Reference Citation Analysis]
29 Liu Y, Lan X, Wu T, Lang J, Jin X, Sun X, Wen Q, An R. 99mTc-labeled SWL specific peptide for targeting EphA2 receptor. Nuclear Medicine and Biology 2014;41:450-6. [DOI: 10.1016/j.nucmedbio.2014.03.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
30 Barile E, Wang S, Das SK, Noberini R, Dahl R, Stebbins JL, Pasquale EB, Fisher PB, Pellecchia M. Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system. ChemMedChem 2014;9:1403-12. [PMID: 24677792 DOI: 10.1002/cmdc.201400067] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
31 Barton WA, Dalton AC, Seegar TC, Himanen JP, Nikolov DB. Tie2 and Eph receptor tyrosine kinase activation and signaling. Cold Spring Harb Perspect Biol 2014;6:a009142. [PMID: 24478383 DOI: 10.1101/cshperspect.a009142] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
32 Posthumadeboer J, Piersma SR, Pham TV, van Egmond PW, Knol JC, Cleton-Jansen AM, van Geer MA, van Beusechem VW, Kaspers GJ, van Royen BJ, Jiménez CR, Helder MN. Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery. Br J Cancer 2013;109:2142-54. [PMID: 24064975 DOI: 10.1038/bjc.2013.578] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.2] [Reference Citation Analysis]
33 Duggineni S, Mitra S, Lamberto I, Han X, Xu Y, An J, Pasquale EB, Huang Z. Design and Synthesis of Potent Bivalent Peptide Agonists Targeting the EphA2 Receptor. ACS Med Chem Lett 2013;4. [PMID: 24167659 DOI: 10.1021/ml3004523] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
34 Funk SD, Orr AW. Ephs and ephrins resurface in inflammation, immunity, and atherosclerosis. Pharmacological Research 2013;67:42-52. [DOI: 10.1016/j.phrs.2012.10.008] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 5.2] [Reference Citation Analysis]
35 Wang S, Noberini R, Stebbins JL, Das S, Zhang Z, Wu B, Mitra S, Billet S, Fernandez A, Bhowmick NA, Kitada S, Pasquale EB, Fisher PB, Pellecchia M. Targeted delivery of paclitaxel to EphA2-expressing cancer cells. Clin Cancer Res 2013;19:128-37. [PMID: 23155185 DOI: 10.1158/1078-0432.CCR-12-2654] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
36 Zozulya SA, Udovichenko IP. [Eph family receptors as therapeutic targets]. Bioorg Khim 2012;38:267-79. [PMID: 22997698 DOI: 10.1134/s106816201203017x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Rodger J, Salvatore L, Migani P. Should I stay or should I go? Ephs and ephrins in neuronal migration. Neurosignals 2012;20:190-201. [PMID: 22456188 DOI: 10.1159/000333784] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
38 Wang S, Placzek WJ, Stebbins JL, Mitra S, Noberini R, Koolpe M, Zhang Z, Dahl R, Pasquale EB, Pellecchia M. Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells. J Med Chem 2012;55:2427-36. [PMID: 22329578 DOI: 10.1021/jm201743s] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 6.5] [Reference Citation Analysis]
39 Noberini R, Mitra S, Salvucci O, Valencia F, Duggineni S, Prigozhina N, Wei K, Tosato G, Huang Z, Pasquale EB. PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity. PLoS One 2011;6:e28611. [PMID: 22194865 DOI: 10.1371/journal.pone.0028611] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
40 Tian W, Xu Y, Han X, Duggineni S, Han X, Huang Z, An J. Development of a Novel Fluorescence Polarization–Based Assay for Studying the β-Catenin/Tcf4 Interaction. J Biomol Screen 2012;17:530-4. [DOI: 10.1177/1087057111429745] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
41 Noberini R, Lamberto I, Pasquale EB. Targeting Eph receptors with peptides and small molecules: progress and challenges. Semin Cell Dev Biol 2012;23:51-7. [PMID: 22044885 DOI: 10.1016/j.semcdb.2011.10.023] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 6.2] [Reference Citation Analysis]
42 Himanen JP. Ectodomain structures of Eph receptors. Semin Cell Dev Biol 2012;23:35-42. [PMID: 22044883 DOI: 10.1016/j.semcdb.2011.10.025] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
43 Noberini R, De SK, Zhang Z, Wu B, Raveendra-Panickar D, Chen V, Vazquez J, Qin H, Song J, Cosford ND, Pellecchia M, Pasquale EB. A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors. Chem Biol Drug Des 2011;78:667-78. [PMID: 21791013 DOI: 10.1111/j.1747-0285.2011.01199.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
44 Wang P, Wang L, Ding ZL, Zeng KF, Jin HL, Zhu H, Shi RH. Expression of EphA2 under hypoxia promotes vasculogenic mimicry in esophageal squamous cell carcinoma cells. Shijie Huaren Xiaohua Zazhi 2011; 19(10): 996-1000 [DOI: 10.11569/wcjd.v19.i10.996] [Reference Citation Analysis]